Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03555422
Title Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Karyopharm Therapeutics Inc
Indications

uterine carcinosarcoma

endometrial cancer

Therapies

Selinexor

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | CAN | BEL


No variant requirements are available.